Search Within

Population Sciences Research Program

  1. "Nursing"
  2. "David Straus"
  3. "Survivorship Research"
  4. "John Gerecitano"
Formats
  1. Meeting Abstract (15)
  2. Journal Article (4)
Groups
  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. Hematologic Malignancies, Division of (19)
  4. Lymphoma (19)
  5. Nursing (19)
  6. Survivorship Research (19)

More Groups

People
  1. Andrew Zelenetz (19)
  2. Craig Moskowitz (19)
  3. David Straus (19)
  4. John Gerecitano (19)
  5. Paul Hamlin (19)
  6. Steven Horwitz (19)

More People

Years
  1. 2018 (1)
  2. 2017 (5)
  3. 2016 (4)
  4. 2015 (3)
  5. 2014 (3)
  6. 2013 (1)

More Years

Publications
  1. Blood (10)
  2. Hematological Oncology (3)
  3. Journal of Clinical Oncology (3)
  4. Blood Cancer Journal (1)
  5. Haematologica (1)
  6. Lancet Oncology (1)
Publishers
  1. American Society of Hematology (10)
  2. American Society of Clinical Oncology (3)
  3. Wiley Blackwell (3)
  4. Elsevier Science, Inc. (1)
  5. Ferrata Storti Foundation (1)
  6. Nature Publishing Group (1)

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay
    Journal Article

    Intlekofer, A. M.; Joffe, E.; Batlevi, C. L.; Hilden, P.; He, J.; Seshan, V. E.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, C. H.; Portlock, C.; more...
    Blood Cancer Journal (2018)

    Fulltext@MSK | Save
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save